CC
PBLS

Casdin Capital’s Parabilis Medicines Inc PBLS Stock Holding History

Casdin Capital’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Buy
+645,690
New +$17.8M 0.88% 22

Other funds holding PBLS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Casdin Capital's PBLS Position: Q2 2026 in Review

Casdin Capital opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 645,690 shares worth $17.7M. The stake represents 0.88% of the portfolio and ranks #22 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • Casdin Capital held 645,690 shares of Parabilis Medicines Inc worth $17.7M as of Q2 2026.
  • Parabilis Medicines Inc was a new Casdin Capital position in Q2 2026.
  • Parabilis Medicines Inc made up 0.88% of Casdin Capital's portfolio in Q2 2026, its #22 holding.
  • 79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.